Dabigatran–idarucizumab reversal during cardiopulmonary bypass
A PK/PD model coupling dabigatran systemic and bypass-circuit disposition to effect-site concentration and idarucizumab exposure during cardiopulmonary bypass.
- Therapeutic
- Dabigatran and idarucizumab
- Target
- Not reported
- Disease
- Preclinical anticoagulation reversal during cardiopulmonary bypass
Biological model
A PK/PD model coupling dabigatran systemic and bypass-circuit disposition to effect-site concentration and idarucizumab exposure during cardiopulmonary bypass.
Intervention
Dabigatran and idarucizumab
Biological focus
PKPD
Context
Preclinical anticoagulation reversal during cardiopulmonary bypass
Model details
A PK/PD model coupling dabigatran systemic and bypass-circuit disposition to effect-site concentration and idarucizumab exposure during cardiopulmonary bypass.
Modeled states
- cpb auc mg min lmg*min/L
Modeled dynamic state for cpb auc mg min l.
- cpb elapsed minmin
Modeled dynamic state for cpb elapsed min.
- dab central mgmg
Modeled dynamic state for dab central mg.
- dab peripheral mgmg
Modeled dynamic state for dab peripheral mg.
- effect conc mg lmg/L
Modeled dynamic state for effect conc mg l.
- idarucizumab mgmg
Modeled dynamic state for idarucizumab mg.
- pump mgmg
Modeled dynamic state for pump mg.
Key readouts
- Central dabigatran concentrationunknown
Model-derived readout for central dabigatran concentration.
- Dabigatran effect-site concentrationmg/L
Model-derived readout for dabigatran effect-site concentration.
- Bypass-circuit dabigatran concentrationunknown
Model-derived readout for bypass-circuit dabigatran concentration.
- Idarucizumab concentrationunknown
Model-derived readout for idarucizumab concentration.
- Mean bypass dabigatran concentrationunknown
Model-derived readout for mean bypass dabigatran concentration.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
CPB dabigatran and idarucizumab reversal
How do bypass-circuit exchange and idarucizumab exposure change dabigatran concentration and effect-site reversal? Explore this biological starting configuration through Central dabigatran concentration, Dabigatran effect-site concentration, Bypass-circuit dabigatran concentration, Idarucizumab concentration, Mean bypass dabigatran concentration. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do bypass-circuit exchange and idarucizumab exposure change dabigatran concentration and effect-site reversal?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do bypass-circuit exchange and idarucizumab exposure change dabigatran concentration and effect-site reversal?
cl std l min 70kg
Model parameter controlling cl std l min 70kg.
Exploratory range around the default value.
5 evenly spaced values in L/minute. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Dabigatran-idarucizumab pharmacokinetics-pharmacodynamics in sheep undergoing cardiopulmonary bypassPerfusion
